• The company will present an overview of business operations and its pipeline, including the Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disorders
• The initial indication of lead drug candidate TRP-8802 is for fibromyalgia, but Tryp believes that psilocybin can be used for much more in the realm of unmet medical needs
• PFN’s development for its proprietary drug candidate, TRP-8803, focuses on increased efficacy, natural blood-brain barrier penetration, enhanced safety and toxicity profiles, reduced risk of abuse, and reduced risk of addiction

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a San Diego-based pharmaceuticals company, has joined the lineup of presenters at this year’s Canaccord Genuity Virtual Growth Conference, to be held virtually on August 10-12. Tryp is focused on developing psilocybin-based clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways (https://ibn.fm/gxu6h). Tryp Chairman and CEO Greg McKee stated that the company would be presenting an overview of the business and its pipeline – including Tryp’s Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disorders. Tryp’s presentation will be held on August 10 at 3 p.m. EST. Register to view the presentation at https://ibn.fm/ja8ep. Prior to this announcement, Tryp released a broadcast titled, “Psychedelics – Not Just for Mental Health Anymore,” highlighting the historical knowledge of psychedelics, such as peyote and psilocybin, and their healing effects, (https://ibn.fm/6c1sq). Modern-day research was hindered by the Controlled Substances Act of 1970, classifying psychedelics as Schedule I drugs with no medical use. In the last few years, research has been lifting this stigma, including research done by Johns Hopkins Medical showing that two doses of psilocybin in combination with psychotherapy generated reduced symptoms for adults suffering from major depression. (can we link to the trial here). Many psychedelic companies have focused on depression, but Tryp is confident that psilocybin can effectively treat other underserviced indications, including chronic pain and certain eating disorders. Tryp’s PFN program is focused on the development of psilocybin-based drug therapy for certain neuropsychiatric disorders. The psilocybin-based therapies have distinct advantages over other drugs currently on the market or in development, including:

• Increased efficacy
• Natural blood-brain barrier penetration
• Enhanced safety and toxicity profiles
• Reduced risk of abuse
• Reduced risk of addiction

PFN features Tryp’s lead drug candidate, TRP-8802, with an initial indication of fibromyalgia. Tryp plans to seek FDA approval to proceed to Phase 2a clinical trials to evaluate the drug as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients found in TRP-8802. So far in 2021, Tryp has achieved significant milestones, which include expanding its roster of world-class scientific advisors, initiating collaborations with world-renowned research institutions to advance clinical trials, advancing the manufacturing capability for synthetic psilocybin, and more. Tryp plans to continue achieving several other milestones before the end of 2021. These milestones include initiating at least two Phase 2a trials, announcing several new clinical research collaborations with leading academic research institutions, successful manufacturing and formulation of GMP synthetic psilocybin using proprietary methods, and filing for additional intellectual property applications. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• GPFT forms strategic alliance with 6PAK Solutions Inc
• Company working to achieve goal of launching Hourglass in Canada in the third quarter of 2021
• Grapefruit’s patented Hourglass delivery cream system has fundamentally changed the way humans absorb cannabinoids

In the United States, Grapefruit USA (OTCQB: GPFT) provides consumers with one of the most effective cannabis topical creams on the market. Now, through its partnership with 6PAK Solutions Inc., Grapefruit can offer its patented Hourglass(TM) Time Release THC+CBD Delivery Topical Relief Cream in Canada too (https://ibn.fm/ofMBY). “We are very encouraged by 6PAK’s decision to form an alliance with Grapefruit to take the initial steps toward obtaining Canadian regulatory approval to bring Grapefruit’s patented time-release THC+CBD topical delivery cream to all Canadians,” said Grapefruit CEO and cofounder Bradley J. Yourist. “6PAK Solutions’ expertise in this area is unrivaled and assures Grapefruit will bring a fully compliant cannabis product to market in Canada. 6PAK is a subsidiary of ATG Pharma, Inc., a leader in regulatory-compliant filling and packaging for the cannabis industry in Canada, so we are in good hands indeed. Our team looks forward to working with Chris Shar and his team in the coming weeks to achieve our corporate goal of introducing Hourglass across the entire nation of Canada in the third quarter of 2021.” Late last month, Grapefruit announced that it had formed a strategic alliance with 6PAK, a well-respected Canadian cannabis manufacturer and arm of ATG Pharma Inc. According to the agreement, GPFT will file a Notice of New Cannabis Product (“NNCP”) with Health Canada; the NNCP outlines the Hourglass production process including the integration of Grapefruit’s patented Z-Pod Xerogel Silica Gel technology into the Hourglass topical delivery cream system. The company hopes to receive approval of the NNCP by third quarter 2021. Once approval is received, the company will work with 6PAK to launch its exclusive Hourglass Time Release THC+CBD Delivery Topical Relief Cream in the Canadian market. “With our strong roots in the Canadian market and service-focused approach, we are proud to offer a platform for Hourglass to bring new and innovative products to the Canadian consumer,” said 6PAK cofounder Chris Shar. Grapefruit’s patented Hourglass delivery cream system is a powerful disruptive delivery technology that has fundamentally changed the way humans absorb cannabinoids such as THC and CBD. Improved absorption means improved benefits, and THC and CBD are purported to provide a host of holistic advantages. A simple application of Grapefruit’s Hourglass cream on the skin is all that is needed for users to enjoy the full-body entourage effects and related relief provided by THC and other beneficial cannabinoids. Because Grapefruit is the exclusive licensee of the Z-Pod Xerogel Silica Gel for cannabis products in North America and the only company that knows how to manufacture the Hourglass time-release delivery cream using the xerogel gel, the company can lay claim to the unique benefits the cream provides. Joining the Grapefruit team, which notes that Hourglass is the future of healthy cannabis delivery systems, are its approved retailers located throughout the United States, Canada and Mexico. Grapefruit holds California permits and licenses to both manufacture and distribute cannabis products in the Golden State. The company’s extraction laboratory and manufacturing and distribution facilities are located in the industry-recognized Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, located on the extension of North Canyon Road, approximately 14 miles north of downtown Palm Springs. To find out more about the company and its game-changing Hourglass time-release cannabinoid delivery cream, please visit www.GrapefruitBlvd.com. NOTE TO INVESTORS: The latest news and updates relating to GPFT are available in the company’s newsroom at https://ibn.fm/GPFT

• Company announces official approval for its common shares to be listed, traded on NYSE American
• Cybin will commit resources to reach the broadest investor audience, accelerate efforts to position Cybin as sector leader
• Companies that list on NYSE American can leverage a wide range of advantages

In an historic move, Cybin (NEO: CYBN) (NYSE American: CYBN) will become the first psychedelic biotech company to trade on the NYSE American LLC stock exchange (https://ibn.fm/LQryy). Cybin received official approval for its common shares to be listed and traded on NYSE American last week, and the company anticipates that shares will start trading on or about August 5, 2021, under the symbol CYBN. “We are all delighted to receive this approval from the NYSE American and are thankful to our wonderful team and loyal investor base who have followed us on this journey so far,” said Cybin CEO Doug Drysdale. “As the first psychedelic biotech company that will now trade on this esteemed exchange in the U.S., we will commit resources to reach the broadest investor audience with our mission and will continue to accelerate our efforts to position Cybin as a leader in the sector.” Drysdale noted that the company expected that expanded access to investors would further fuel Cybin’s mission to develop revolutionary psychedelic therapeutics for patients suffering from mental health conditions (https://ibn.fm/TssUu). Designed for growing companies, the NYSE American exchange draws on its heritage as the American Stock Exchange and offers investors greater choice in how they trade (https://ibn.fm/wOUM7). The exchange is a competitively priced venue that blends unique features derived from the NYSE, such as electronic designated market makers (e-DMMs) with quoting obligations for each NYSE American-listed company, with NYSE Arca’s fully electronic price/time priority execution model. Companies that list on the NYSE American can leverage a wide range of advantages, including access to capital, improved branding and visibility, accountability, and increased liquidity. Cybin also noted that, in addition to listing and trading on the NYSE American in U.S. dollars, Cybin’s common shares will continue to be listed and trade in Canada on the NEO Exchange in Canadian dollars, also under the symbol CYBN. Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Patented NeuroCap(TM) and NeuroEEG(TM) devices can be used anywhere, ideal for clinical research labs, neurology clinics, urgent care clinics, emergency departments, ICUs, assisted living facilities, and nursing homes
• Current global market for EEG devices estimated at $956.1 million in 2020, expected to reach $1.6 billion revenue by 2026, CAGR of 8.7% between 2019-2026

Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company, focuses on developing cost-effective next-generation medical devices and software with the goal of modernizing and increasing accessibility to brain diagnostics for the rapidly growing neurology market. Brain Scientific’s patented NeuroCap(TM) and NeuroEEG(TM) devices are positioned to disrupt the expensive EEG market. Company’s Neurotech ecosystem consists of devices that are affordable and sustainable FDA cleared alternatives to the EEG technology seen today. Devices can be used in a wide range of settings, including remote clinical research labs, neurology clinics, urgent care clinics, emergency departments, ICUs, assisted living facilities, and nursing homes. The NeuroCap – an FDA-cleared disposable pre-gelled EEG headset – features 22 electrodes and 19 active EEG channels that can be used for recording EEGs in nearly any setting. It is complemented by the NeuroEEG, an FDA-cleared portable clinical-grade wireless EEG amplifier that acquires, records, displays and transmits electrical brain activity. In the future company’s technology will leverage AI and ML technology with an extensive database comprised of normal and abnormal brain data to help detect abnormal activity associated with brain-related diseases like epilepsy, dementia and pre-Alzheimer’s disease. With a cloud-based infrastructure, the devices will be able to collect, aggregate and analyze data, resulting in the rapid development of algorithms that can accurately detect neurological disorders. The company’s three-stage development process commenced with the first phase in 2018 that resulted in the creation of the NeuroCap and NeuroEEG. The second phase – currently ongoing – is focused on the development of essential cloud-based infrastructure that will be used to transmit data between patients and neurologists. The third and final phase, scheduled for later this year and into 2022 and 2023, will focus on the development of AI and ML processes to increase efficiency, consistency, and accuracy of diagnostic analytics provided by the application. According to Grandview Research, the current global EEG device market was estimated at $956.1 million in 2020 and is expected to reach $1.6 billion revenue by 2026 with an expected CAGR of 8.7% between 2019-2026 (https://ibn.fm/HYehK). Currently, over 150 million people are diagnosed globally with epilepsy, dementia and Alzheimer’s disease, and BRSF management expects the market for neurodiagnostic devices to expand in tandem with the growth of neurological disorders throughout the world (https://ibn.fm/a0AEW). Brain Scientific Inc. aims to address this target market by providing next-generation EEG devices that will leverage AI and ML technology to facilitate the early diagnosis of brain disorders. With a rock-solid commercialization strategy and diverse management team of experts, Brain Scientific is positioned to lead the market in cost-effective portable EEG devices that enable medical professionals to diagnose patients with efficiency, consistency and accuracy in virtually any setting. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Company enters into MOU to acquire auto import/export company
• Opportunities are to maintain excellence, leverage channels to grow sales
• DSG anticipates seeing impressive results soon after closing, plans to increase cash flow with positive revenue

In a move that provides immediate sales opportunities, DSG Global (OTCQB: DSGT) announced that it has entered into a binding memorandum of understanding to acquire MTG Inc., an established automotive import/export company based in Ontario (https://ibn.fm/gZE00). MTG operates in Canada, the United States and Mexico and has extensive commercial fleet and retail connections throughout the global automotive industry. “We are acquiring a proven entity and the talent that built it,” stated DSG Global CEO Bob Silzer. “MTG and [Johnny] Cooper’s previous company have completed well over a billion dollars in sales. The opportunities before us are to maintain the excellent company they have built and leverage their sales and distribution channels for growing our electric vehicle sales more expediently.” According to the company, the transaction should be complete sometime in third quarter 2021, subject to several conditions. Once the acquisition is finalized, MTG’s customer base and multimillion-dollar monthly sales will be integrated into a new division — DSG Wholesale Division — led by renowned automotive specialists Michael Tersigni and Johnny Cooper. Cooper has invaluable experience with this business model, having created a company in the late 1990s that completed transactions for more than 12,000 vehicles totaling up to $321 million in sales annually; that company was sold to one of the largest auto auction groups in the world. The company noted that the MTG acquisition allows it to immediately expand cross-border sales for both new and late-model vehicles; the strategic move will afford MTG’s current and future fleet and consumer channels strong trade-in values on electric vehicles purchased from Imperium, along with a large dealer base creating sales for Imperium Motors. DSG anticipates the division will see impressive results soon after closing and plans to increase cash flow with positive revenue as well as enhance its own EV business by offering a unique buying experience to Imperium clients. DSGW will be one of the only OEM EV companies offering to take used inventory and dispose of the units, making it the go-to full-service provider of world-class EV products for fleet and consumer transportation. The strategic timing of this move is ideal for the company. “Every business proposition boils down to when, how and how much,” said Silzer. “Well, when is now, in that we have SUVs, trucks, sedans and other vehicles either in port or arriving soon. How we are getting product to market is explained via this acquisition and the dealers with whom we will work. Both our manufacturing partners have no issues obtaining critical computer chips, therefore no delivery delays, as several manufacturers have experienced. And the how much could have been a relevant question if we had not purchased MTG to be a wholesale distribution network. “Because of this opportunity, we are really only left with the all-important question of how much the Imperium brands will cost consumers,” Silzer concluded. “The answer is, surprisingly less than many other EVs. For example, the ET5 SUV comes extremely well-equipped at around $40,000 less available incentives and tax credits in most cases.” DSG Global is an emerging global technology company with an array of interconnecting businesses in some of the fastest-growing market sectors. With roots in the golf industry, in which it specializes in fleet management with patented analytics, mobile touch-screen engagement and electric golf carts under the Vantage Tag Systems (“VTS”) brand, the company is moving quickly with road-ready electric vehicles for sale in the third quarter of 2021 through its Imperium Motor Company subsidiary. For more information, visit the company’s website www.DSGTGlobal.com. NOTE TO INVESTORS: The latest news and updates relating to DSGT are available in the company’s newsroom at https://ibn.fm/DSGT

Online Livestreaming Event Date: August 16-17, 2021 Clinical researchers, medical managers, pharma companies, and life science professionals are invited to attend the 2nd Electronic Trial Master File (“eTMF”) Forum on August 16-17th, 2021. This 2-day event will offer a leading stage to learn the skills of integrated TMF technology for successful clinical research. Attendees will understand the intricacies of identifying the challenges and risks posed during clinical research. They will learn to identify how to protect the data gathered during the research trials, meeting regulatory requirements, preparing for audits, getting ready for inspections, and lucrative techniques for monitoring and filing correspondence. The event is powered by the Scaritt Group, Inc. and the TMF Professionals. The 2nd eTMF Forum is hosted by Dynamic Global Events (“DGE”), a Life Science Leader in organizing B2B Events. The Global Event Company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries. The 2nd Electronic Trial Master File Forum is an online live streaming event that will witness the leading industry stalwarts from around the globe sharing their opinion, views and perspective about seamlessly conducting clinical trial research. Some important elements of the event’s agenda include:

• Stay ahead in competition through advanced inspection readiness solutions
• Data privacy risks and challenges for intellectual property
• Improving collaboration techniques between CROs and sites
• Ensure a secure quality monitoring and quality-control procedure
• Communicate the expectation of the completion time of a completeness review
• Communicate the work instructions among the sponsors and third parties and align with SOPs

The 2nd Electronic Trial Master File Forum is of special interest to Solution Providers, Paper and Electronic Archiving systems, Clinical Research Organizations, Data Records Managers, and eTMF Service Providers, who will get an overview of pre and post-inspection readiness and recognize the importance of timing and readability. They will further learn the use of technology for maximum integration and explore completeness review from a resourcing and staffing perspective. Speakers at the event will discuss how an inspection ready TMF requires a comprehensive approach, accounting for variables, and sound evaluation of parameters that could go wrong. Refining collaborative processes with CROs and understanding their requirements and motivations are some of the key lessons that will be discussed at the Forum. To know more about the event, please visit https://ibn.fm/9Qfkt

• Pet CBD industry projected to reach $1.7 billion by 2025
• GPFT’s new pet CBD product targets two common dog, cat ailments: anxiety and joint pain
• Pets deserve the same relief that their owners experience with Grapefruit’s CBD products, says CEO

Humans aren’t the only ones who may benefit from all that cannabidiol (“CBD”) offers. A recent Brightfield Group article reported that the pet CBD industry has experienced significant growth over the last several years, with Brightfield projecting an expected market valuation of more than $1.7 billion by 2025 (https://ibn.fm/jbMU2). Grapefruit USA (OTCQB: GPFT) is leveraging its expertise in the space by launching a new USDA-certified Organic CBD Pet Tincture. “We understand that pet owners are now demanding organic, plant-based, natural remedies to keep their furry family members calm and in good health, and avoid the potential negative side effects of generic, synthetic pet medications,” said Bradley Yourist, cofounder and CEO of GPFT. “Grapefruit’s new Pet CBD Tincture meets this pet-owner market demand because it is derived from hemp grown right here in the U.S., and each batch is lab tested for purity.” A premiere, fully licensed, California-based cannabis company, Grapefruit is expanding its hemp-based CBD product line with the new pet tincture, which targets two of the most common dog and cat ailments: anxiety and joint pain. Grapefruit’s new Pet 300 mg CBD hemp-based tincture is derived from USDA-certified organic hemp, grown in the United States. “Our commitment to obtain the USDA-certified organic seal clearly demonstrates GPFT’s continued commitment to creating the best high-quality, safe and effective CBD products for our customers, be they human, feline, canine or otherwise,” Yourist continued. “Our pets deserve the same relief that their owners have experienced with our other CBD products, such as our THC-free, hemp-derived CBD Hourglass time-release topical relief cream.” Grapefruit noted that overall pet ownership is increasing, partly due to the pandemic, with more than half of all U.S. households having a furry family member. In addition, research shows that more than 64% of CBD consumers buy CBD products for their pets because of the holistic benefits they provide. The global CBD pet market size was valued at $27.7 million in 2019 and is expected to grow at a compound annual growth rate (“CAGR”) of 40.3% from 2020 to 2027. With its expertise in the CBD space, Grapefrult is ideally positioned to be a strong presence in this market. Grapefruit holds California permits and licenses to both manufacture and distribute cannabis products in the Golden State. The company’s extraction laboratory and manufacturing and distribution facilities are located in the industry-recognized Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, located on the extension of North Canyon Road, approximately 14 miles north of downtown Palm Springs. To find out more about the company and its game-changing Hourglass time-release cannabinoid delivery cream, please visit www.GrapefruitBlvd.com. NOTE TO INVESTORS: The latest news and updates relating to GPFT are available in the company’s newsroom at https://ibn.fm/GPFT

• ACP operates in two states and has strategic plans in place to expand into two more by 2024
• Partnerships have allowed the recreation of the exact soil conditions, growing supplements, water makeup, and environment of Orange Hill in Jamacia
• Junior Gordon, the Cultivation Manager of ACP, is an award-winning and highly sought after grower whose focus is primarily on plant health

The privately-owned American Cannabis Partners (“ACP”), a large scale organic cannabis cultivation company, is headquartered in Northern California but also has a foothold in Michigan. Since its beginning in 2018, ACP has acquired 12 cannabis licenses, 20,000 sq. ft of cultivation license in California, and 540,000 sq ft. of cultivation licenses and one retail license in Michigan. The company has plans to expand into its third U.S. state in 2022 and it’s fourth in 2024. The company prides itself in the level of detail given to growing its plants. Partnerships with Soilscapes and Link4 Systems have allowed the company to create exact soil conditions, growing supplements, water makeup, and environments that mimic Orange Hill in Jamacia. This has resulted in yields well above industry norms and the production of some of the most sought-after flower in the U.S. According to Gary Coltek, COO of ACP, the flower is so sought after that the entire crop of the new patent-pending strains, sold exclusively under the brand ZUK has been pre-sold for 2021 (https://ibn.fm/LNjoN). Junior Gordon, the Cultivation Manager of American Cannabis Partners, is a High Times Cannabis Cup and Ganjamaica Cup Winner and one of the top-ranked growers in the world (https://ibn.fm/UJnsQ). Gordon and his team focus daily on plant health which is one of the many reasons the final product is in constant demand. This attention to detail results in uniform, clean, and beautiful plants that are of the highest quality. The company believes strongly in conducting business in a way that benefits and does not harm the environment, employee, and customer experience. Therefore, as they seek out additional partnerships, they want to ensure that those who join them hold the same high values. These values include sustainable operating practices that reduce ACP’s environmental footprint while increasing social responsibility. This is achieved by:

• Local purchasing and employment
• Environment-friendly products
• Energy and water conservation efforts
• Waste management program that positively impacts people, planet, and profit

Part of ensuring that these values are maintained requires that ACP looks for real estate listings in cannabis-friendly states with a population demand, agricultural zoning, and available license. The land and equipment purchased by the company are paid for in full to remain debt-free. Once acquired, cost-effective measures are put into place to increase the market value of the land. American Cannabis Pertners is focused on four industry segments that include real estate, cultivation, medical research, and non-profit groups. The company supplies multiple forms of raw product at wholesale prices and provides stable profit margins for customers. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP

• FuelPositive is providing commercially viable and sustainable clean energy solutions through its flagship and proprietary technology for carbon-free ammonia
• The majority of ammonia used today (80%) is in the agriculture industry, with more minute percentages in waste, water treatment, antiseptic, refrigerants, textile, mining, and pharmaceuticals
• Co-inventor and engineer Dr. Ghassan Chehade has accepted the position of Lead Project Engineer with FuelPositive Corp.
• FuelPositive selected Natural Compressed Air Canada Ltd. to undertake the manufacturing of the Company’s second phase hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production
• The existing global ammonia market is expected to grow from $52.71 billion in 2017 to $81.42 billion by 2025. The carbon-free global ammonia markets could see much more dramatic growth

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company that is focused on manufacturing, licensing, partnership, and acquisition opportunities that build upon various technological achievements, has announced that it has appointed Dr. Ghassan Chehade as Lead Project Engineer. Dr. Chehade is an engineer and co-inventor named on the provisional patent for FuelPositive’s proprietary technology to produce carbon-free ammonia. He worked with Dr. Ibrahim Dincer on the original development of the NH3 technology, according to a company press release (https://ibn.fm/GhH4K). FuelPositive is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (“NH3”), for use across a broad spectrum of industries and applications. The company’s flagship carbon-free ammonia technology provides an innovative solution to the hydrogen economy’s current challenges. Traditional NH3 manufacturing exists on a large scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. A total of approximately 200 million metric tonnes of NH3 are consumed each year – the majority used in the agricultural sector. According to a Fior Markets report, the global ammonia market is expected to grow from $52.71 billion in 2017 to $81.42 billion by 2025, expanding at a CAGR of 5.59%. Agriculture accounts for more than 80% of the global ammonia use. Smaller percentages can be attributed to waste, water treatment, antiseptic, refrigerants, textile, mining, and pharmaceuticals (https://ibn.fm/3uFOR). According to a July 5 report, the global green ammonia market size is expected to expand at 54% of CAGR by 2025. (https://ibn.fm/7Xvle). The technology developed by Dr. Dincer and Dr. Chehade allows for in-situ production of NH3 in an entirely sustainable manner, using only water, air, and sustainable electricity. The production of hydrogen is energy intensive, but it is just one of the variables that hinder the hydrogen economy’s growth. The hurdles include:

• Storage – the storage by compression or liquification is both cost-prohibitive and unsustainable
• Distribution – the network for effective hydrogen deployment has yet to be developed due to the enormous infrastructure costs
• End-Use – transportation-related end-use applications are still in their infancy, but almost any vehicle on the road today can be easily converted to operate on 100% carbon-free ammonia at a considerably low cost per mile

“Ghassan will play a significant role, working closely with National Compressed Air Canada Ltd., as we manufacture our Phase 2 commercial prototype demonstration systems for carbon-free NH3 production,” said Ian Clifford, the CEO of FuelPositive. “The manufacturing of demonstration prototypes is a major milestone for us as we transition from research and development to the commercialization phase of our growth. Having Ghassan involved daily will ensure success, preparing us for the rollout of our demonstration pilot projects in early 2022,” Clifford added. “I am very excited to join Fuel Positive as a Lead Project Engineer. I look forward to working with Ian and his team on advancing this important technology to the next phase,” said Ghassan Chehade. In May, FuelPositive announced that it selected Natural Compressed Air Canada Ltd. to undertake the manufacturing of the company’s second phase hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production. One of the key benefits of FuelPositive’s technology is the flexibility allowing for small, medium, or large-scale production of NH3 on location, minimizing or even eliminating challenges and volatility associated with storage, distribution, and end-use. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• New cultivators have approved for federally funded studies in the U.S., and 575 DEA-licensed researchers are standing by, ready for the change
• RYAH’s ecosystem of products allows data to be collected from seed to consumption, providing a holistic view of the plant necessary for optimal research
• RYAH continues to expand its global clinical and distribution network for plant-based medicine and digital patient care

The U.S. is putting an end to its 50-year long prohibition on Cannabis Research (https://ibn.fm/YIrkv). New cultivators have now been approved for federally funded studies. With over 575 DEA-licensed researchers across the U.S., the future of cannabis research and insights into the medicinal and therapeutic properties of cannabis products consumers and patients are using looks promising. RYAH Group (CSE: RYAH) (formerly RYAH Medtech) is standing by, ready to provide a wealth of smart devices, artificial intelligence, and an integrated platform that will fully support the U.S. as it explores the benefits, risks, and effects of cannabis. U.S. researchers can benefit from RYAH Group’s state-of-the-art IoT suite of products. The technology collects, analyzes, and leverages objective data throughout the research process. As a result, the Company boasts one of the largest plant-based medicine databases globally with 200,000 plus registered users. The Company’s ecosystem of products allows data to be collected from seed to consumption, providing a holistic view of the plant necessary for optimal research. The seed to consumption data collection is accomplished by working with all players in the plant’s lifecycle. RYAH Group partners with growers, dispensaries, clinical researchers, producers, and consumers. One of the major challenges for researchers is regulating dose size because cannabis is a chemically variable plant. RYAH Group specializes in precision dose control technology that helps to control this variable in a clinical setting. The U.S. is about to embark on exciting research previously prohibited. Most cannabis studies in the U.S. to this point have been anti-cannabis in nature, focused on crime, dependence, abuse, and use in adolescents (https://ibn.fm/c2xwp). The changes in federal regulations means that research can now openly be conducted to seek out the medicinal and therapeutic benefits. The U.S. is finally ready to move past the negatives of cannabis and truly explore the many potential benefits of this plant. RYAH Group has been working with researchers across the globe to discover the benefits of cannabis’ various therapeutic and medicinal uses.

• IoT devices and cloud-based data analytics available to pre-clinical and clinical trials in New Zealand (https://ibn.fm/uhR9L)
• Providing thousands of dose-measuring devices and dry-herb cartridges over a five year period to an oncology clinic in the U.K. for the study of chronic pain (https://ibn.fm/wu4Jl)
• Participating in a study with the University of Milan to acquire the necessary data for an accurate milligram dosing experience with dry herb (https://ibn.fm/7OzyN)

RYAH Group continues to expand its global clinical and distribution network for plant-based medicine and digital patient care, providing the most holistic approach to plant treatment research available on the market. As a leading digital health care analytics and technology company, RYAH Group is able to support critical clinical studies and positively impact the future treatment of patients for a wide range of medical conditions. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH